BRIEF published on 09/11/2024 at 07:35, 2 years 1 month ago Medincell établit un nouveau contrat de liquidité avec Rothschild Martin Maurel Euronext Paris Contrat De Liquidité Rothschild Martin Maurel Actions Ordinaires Medincell
BRIEF published on 09/11/2024 at 07:35, 2 years 1 month ago Medincell establishes a new liquidity contract with Rothschild Martin Maurel Common Shares Euronext Paris Liquidity Contract Rothschild Martin Maurel Medincell
PRESS RELEASE published on 09/11/2024 at 07:30, 2 years 1 month ago Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité Medincell confie son Contrat de liquidité à ROTHSCHILD MARTIN MAUREL pour animer ses actions sur Euronext Paris, conformément à la réglementation en vigueur Euronext Paris Contrat De Liquidité Rothschild Martin Maurel Réglementation Medincell
PRESS RELEASE published on 09/11/2024 at 07:30, 2 years 1 month ago Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract Medincell appoints ROTHSCHILD MARTIN MAUREL for liquidity contract management on Euronext Paris, complying with AMF Decision 2021-01 Euronext Paris Liquidity Contract Rothschild Martin Maurel AMF Decision Medincell
BRIEF published on 09/05/2024 at 07:35, 2 years 1 month ago Medincell : avancées prometteuses pour l'Olanzapine injectable Schizophrénie Phase 3 Medincell Olanzapine Teva Pharmaceuticals
BRIEF published on 09/05/2024 at 07:35, 2 years 1 month ago Medincell: Promising advances for injectable Olanzapine Schizophrenia Phase 3 Medincell Olanzapine Teva Pharmaceuticals
PRESS RELEASE published on 09/05/2024 at 07:30, 2 years 1 month ago Informations privilégiées / Autres communiqués Teva, partenaire de Medincell, annonce des avancées importantes dans l'essai clinique pivot de phase 3 de l'Olanzapine injectable à durée d’action prolongée, avec un taux élevé d'injections réalisées et des résultats positifs attendus Schizophrénie Essai Clinique Medincell Olanzapine Teva
PRESS RELEASE published on 09/05/2024 at 07:30, 2 years 1 month ago Inside Information / Other news releases Teva provides update on pivotal Phase 3 of Olanzapine LAI by Medincell. Safety results on track for H2 2024. Potential innovative long-acting antipsychotic treatment Clinical Trials Phase 3 Medincell Teva Olanzapine LAI
BRIEF published on 08/20/2024 at 17:52, 2 years 2 months ago Modalités de participation à l’Assemblée Générale de Medincell Actionnaires Assemblée Générale Vote À Distance Medincell Videoconference
BRIEF published on 08/20/2024 at 17:52, 2 years 2 months ago Terms of participation in the Medincell General Meeting Shareholders General Assembly Remote Voting Medincell Videoconference
Published on 10/30/2026 at 23:35, 45 minutes ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 50 minutes ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 3 hours 33 minutes ago CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 5 hours 20 minutes ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 8 hours 50 minutes ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/30/2026 at 22:49, 1 hour 31 minutes ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 5 hours 42 minutes ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 23:00, 1 hour 20 minutes ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 23:00, 1 hour 20 minutes ago Biophytis publie les résultats du premier semestre 2026 et fait le point sur sa stratégie
